IP Library Granted Patent US 7,615,356
Granted Patent B2
US 7,615,356 · App. 10/620,312 · Granted Nov 10, 2009

Ion channel assay methods

Assignee: Vertex Pharmaceuticals (San Diego) LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,615,356
App. No.
10/620,312
Granted
Nov 10, 2009
Kind
B2
Abstract

A method of characterizing the biological activity of a candidate compound may include exposing cells to the candidate compound, and then exposing the cells to a repetitive application of electric fields so as to set the transmembrane potential to a level corresponding to a pre-selected voltage dependent state of a target ion channel.

Claims (8)

1. A method of high throughput characterization of the biological activity of a candidate compound comprising:

placing a population of cells, solvent, voltage sensitive chemical probes and at least one candidate compound into an area of observation in at least one sample well in a multiwell plate;

exposing said population of cells to electric fields produced by one or more pairs of electrodes disposed within said sample well, wherein said electric fields comprise a first pulse series comprising a first plurality of electric pulses and a second pulse series comprising a second plurality of electric pulses with a pause between the first pulse series and the second pulse series, wherein said pause has a duration that is at least as long as twice the time interval between any two pulses in the first pulse series; and

monitoring changes in transmembrane potential of said population of cells in said sample well by monitoring emission from said voltage sensitive chemical probes during at least a portion of said first pulse series and a portion of said second pulse series in a parallel assay high throughput manner.

2. The method of claim 1 wherein monitoring comprises optically monitoring.

3. The method of claim 2 wherein optically monitoring comprises detecting fluorescence emission of a FRET based voltage sensor from an area of observation containing said population of cells.

4. The method of claim 1 , further comprising comparing data gathered from said first pulse series with data gathered from said second pulse series.

5. The method of claim 1 , wherein the changes in the transmembrane potential are indicative of ion channel recovery from block by said compound.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2016
From: MACQUARIE US TRADING LLC
To: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
Reel/Frame 040357/0001 →
SECURITY INTEREST Recorded Jul 10, 2014
From: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 033292/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2004
From: MAHER, MICHAEL P.; GONZALEZ, JESES E. III
To: VERTEX PHARMACEUTICALS, INC.
Reel/Frame 014911/0806 →
Continuity (3)
Continuation In Part 0980445700 · Mar 12, 2001
Provisional Application 6021767100 · Jul 10, 2000
Related Publication 20040110123A1 · Jun 10, 2004